Article citationsMore>>

Pulliam, S., Karki, N.R., Khan, J., Jogezai, S., Sultan, S., Muhammad, L., Khan, M., Jamil, N., Waheed, A., et al. (2022) PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies? Clinics and Practice, 12, 653-671.
https://doi.org/10.3390/clinpract12050068

has been cited by the following article:

• TITLE: A Review of the Impact of PD-L1 Expression on the Prognosis of Small Cell Lung Cancer

  AUTHORS: Pan Zhu, Yanhua Xu

  KEYWORDS: Small Cell Lung Cancer, PD-L1, PD-1, Immunotherapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.7, July 7, 2023

  ABSTRACT: Small cell lung cancer is an invasive neuroendocrine carcinoma with early metastasis potential. It tends to grow rapidly and metastasize early, with the majority of patients diagnosed as advanced stage small cell lung cancer (ES-SCLC). Systemic treatment consisting of platinum drugs and etoposide chemotherapy is the main treatment method, although the objective effective rate of this combination is 60% - 80%. However, most SCLC patients experience disease progression shortly after initial treatment, with a median overall survival of 10 months. There are few second-line treatment drugs available, and immunotherapy using checkpoint inhibitors has completely changed the treatment of many cancer types. Adding immune checkpoint inhibitors (ICI) to conventional chemotherapy as first-line treatment can improve the survival rate of widespread small cell lung cancer (ES-SCLC), but so far, there are no definitive factors to determine patients who are more likely to benefit from immunotherapy. This review summarizes the results of immunotherapy trials for small cell lung cancer. And a review was conducted on the predictive factors of these trials, with special emphasis on the expression of PD-L1 in small cell lung cancer to determine its clinical value.